LTRN - Lantern Forward P/S Multiple

Lantern Pharma Inc. (LTRN) is accelerating the development of oncology drugs for the brain and lungs by optimizing therapy discovery costs. The forward P/S history confirms this growth, with the metric currently holding around . While RADR digital simulations automate biomarker discovery and replace manual labor, geopolitical data fragmentation requires the company to allocate significant expenditures toward cybersecurity.

The forward P/S ratio determines the market value of Lantern Pharma Inc. (LTRN) relative to expected revenue, allowing for an assessment of whether the asset is overvalued or undervalued through the lens of growth rates. By analyzing the forward P/S metric, an investor can see how the lightweight cloud model of Lantern Pharma Inc. (LTRN) with minimal physical assets impacts capitalization, which determines the long-term investment attractiveness of the business.